246 lines
56 KiB
HTML
246 lines
56 KiB
HTML
|
<!DOCTYPE html>
|
|||
|
|
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
|
|||
|
|
<meta charset="utf-8"/>
|
|||
|
|
<meta content="pandoc" name="generator"/>
|
|||
|
|
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
|
|||
|
|
<title>18 November, 2020</title>
|
|||
|
|
<style>
|
|||
|
|
code{white-space: pre-wrap;}
|
|||
|
|
span.smallcaps{font-variant: small-caps;}
|
|||
|
|
span.underline{text-decoration: underline;}
|
|||
|
|
div.column{display: inline-block; vertical-align: top; width: 50%;}
|
|||
|
|
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
|
|||
|
|
ul.task-list{list-style: none;}
|
|||
|
|
.display.math{display: block; text-align: center; margin: 0.5rem auto;}
|
|||
|
|
</style>
|
|||
|
|
<!--[if lt IE 9]>
|
|||
|
|
<script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
|
|||
|
|
<![endif]-->
|
|||
|
|
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
|
|||
|
|
<body>
|
|||
|
|
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
|
|||
|
|
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li><a href="#from-preprints">From Preprints</a></li>
|
|||
|
|
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
|
|||
|
|
<li><a href="#from-pubmed">From PubMed</a></li>
|
|||
|
|
<li><a href="#from-patent-search">From Patent Search</a></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li><strong>Comparative analysis of antibody- and lipid-based multiplexing methods for single-cell RNA-seq</strong> -
|
|||
|
|
<div>
|
|||
|
|
Multiplexing of samples in single-cell RNA-seq studies allows significant reduction of experimental costs, straightforward identification of doublets, increased cell throughput, and reduction of sample-specific batch effects. Recently published multiplexing techniques using oligo-conjugated antibodies or -lipids allow barcoding sample-specific cells, a process called “hashing”. Here, we compare the hashing performance of TotalSeq-A and -C antibodies, custom synthesized lipids and MULTI-seq lipid hashes in four cell lines, both for single-cell RNA-seq and single-nucleus RNA-seq. Hashing efficiency was evaluated using the intrinsic genetic variation of the cell lines. Benchmarking of different hashing strategies and computational pipelines indicates that correct demultiplexing can be achieved with both lipid- and antibody-hashed human cells and nuclei, with MULTISeqDemux as the preferred demultiplexing function and antibody-based hashing as the most efficient protocol on cells. Antibody hashing was further evaluated on clinical samples using PBMCs from healthy and SARS-CoV-2 infected patients, where we demonstrate a more affordable approach for large single-cell sequencing clinical studies, while simultaneously reducing batch effects.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2020.11.16.384222v1" target="_blank">Comparative analysis of antibody- and lipid-based multiplexing methods for single-cell RNA-seq</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Keeping Kids Busy: Family Factors Associated with Hands-on Play and Screen Time During the COVID-19 Pandemic</strong> -
|
|||
|
|
<div>
|
|||
|
|
Parent-child interactions are crucial for child development. The COVID-19 pandemic has negatively affected mental health and increased parenting challenges impacting parent-child functioning. The aim of the current study was to examine the relationship between parent factors and child activities to identify parental needs. A convenience sample of parents (N = 708), primarily mothers (n = 610; 87.4%) aged 35.59 years old (SD = 5.59; range = 21-72), with children ages 2-8 years completed an online questionnaire between April 14-June 1, 2020. Participants mostly resided in Canada and had an income of >$100,000. Parent-child activities were measured as total weekly time and combined time across activities within two categories: hands-on play and screen time. Bivariate correlations informed block-wise linear regression models. For families with childcare needs, parental anxiety was associated with higher total hands-on play (F(3,142) = 14.01, p < .001), combined hands-on play (F(2,85) = 6.82, p = .011), and combined screen time (F(2,82) = 6.25, p = .014). Families without childcare needs indicated parenting stress was associated with lower total hands-on play (F(3,212) = 7.95, p < .005) and combined hands-on play (F(2,110) = 5.67, p = .019), and higher supervised screen time (F(3,138) = 6.14, p = .014). Family structure and indices of socioeconomic status were also predictive of activities across childcare needs and child ages. To promote high-quality parent-child interactions and positive developmental outcomes in the pandemic, policy makers should support childcare needs, parent mental health and stress, and provide evidence-based guidelines for child screen time.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://psyarxiv.com/prtyf/" target="_blank">Keeping Kids Busy: Family Factors Associated with Hands-on Play and Screen Time During the COVID-19 Pandemic</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Does Emotional Well-Being Mediate Between the Association of Peer Support and Depressive Symptoms in University Students During COVID-19 Pandemic?</strong> -
|
|||
|
|
<div>
|
|||
|
|
The coronavirus (COVID-19) pandemic has adversely affected individuals’ mental health. Social isolation as a result of social distancing during the pandemic potentially affects the associations among perceived available peer support, emotional well-being, and depression in university students. The present study examined the associations among perceived available peer support, emotional well-being (as indicated negatively by loneliness and negative affects, and indicated positively by positive affects and hope), and depressive symptoms in university students. During the 3rd stage of the outbreak in July, 2020, 255 students at a public university in Hong Kong participated in an online-based survey which assessed their perceived available peer support, emotional well-being, and depressive symptoms. Results showed that perceived available peer support negatively contributed to depressive symptoms; both negative and positive indicators of emotional well-being mediated the association between perceived available peer support and depressive symptoms. The university students showed signs of depressive symptoms, highlighting the need for preventive efforts and increased access to mental health care that supports the psychological and emotional needs of young people during the COVID-19 pandemic.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://psyarxiv.com/k5wms/" target="_blank">Does Emotional Well-Being Mediate Between the Association of Peer Support and Depressive Symptoms in University Students During COVID-19 Pandemic?</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>The impact of the coronavirus disease 2019 (COVID-19) outbreak on hospital admissions for alcohol-related liver disease and pancreatitis: a time-series analysis</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Background During the coronavirus disease 2019 (COVID-19) pandemic, there have been health concerns related to alcohol use and misuse. Therefore, the World Health Organization cautioned that alcohol consumption during the pandemic might have a negative impact. The aim of this study was to examine the population-level change in cases of alcohol-related liver disease and pancreatitis that required admission during the COVID-19 outbreak. Methods We included patients aged 18 years or older who were hospitalized between July 2018 and June 2020 using Diagnostic Procedure Combination data, an administrative database in Japan, and counted the admission cases whose primary diagnosis was alcohol-related liver disease or pancreatitis. We defined the period from April 2020, when the Japanese government declared a state of emergency, as the beginning of the COVID-19 outbreak. The rate ratio (RR) of admissions with alcohol-related liver disease or pancreatitis per 1,000 admissions was tested using interrupted time series analysis. In addition, excess admissions for alcohol-related liver disease or pancreatitis were calculated. Results Overall admissions were 3,026,389 cases, and a total of 10,242 admissions for alcohol-related liver disease or pancreatitis occurred from 257 hospitals. The rate of admissions per 1,000 admissions during the COVID-19 outbreak period (April 2020 to June 2020) had a 1.2 times increase compared with the pre-outbreak period (July 2018 to March 2020) for cases of alcohol-related liver disease or pancreatitis (RR: 1.22, 95%Confidence interval [CI]: 1.12 to 1.33). The COVID-19 pandemic caused about 214.75 (95%CI: 178.78 to 249.72) excess admissions for alcohol-related liver disease or pancreatitis based on predictions from our model. Conclusion The COVID-19 outbreak might have resulted in increased hospital admissions for alcohol-related liver disease or pancreatitis.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.16.20232181v1" target="_blank">The impact of the coronavirus disease 2019 (COVID-19) outbreak on hospital admissions for alcohol-related liver disease and pancreatitis: a time-series analysis</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Nasopharyngeal Panbio COVID-19 antigen performed at point-of-care has a high sensitivity in symptomatic and asymptomatic patients with higher risk for transmission and older age</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Background: Performance of point-of-care tests in clinical practice remains undetermined. We aimed to evaluate the performance of the nasopharyngeal Panbio COVID-19 antigen Rapid Test Device in real-life conditions in different clinical scenarios. Method: Prospective study conducted in three primary care centers (PCC) and an emergency department. The antigen test was performed at point-of-care in nasopharyngeal and nasal swabs, and in saliva. Positive and negative percent agreement (PPA, NPA) were calculated with the RT-PCR assay as reference standard. Results: Of 913 patients included, 296 (32.3%) were asymptomatic and 690 (75.6%) came from the PCC. Nasopharyngeal swabs were collected from 913, nasal swabs from 659, and saliva from 611 patients. RT-PCR was positive in 196 (21.5%) nasopharyngeal samples (NPS). Overall PPA (95% CI) in NPS was 60.5% (53.3-67.4), and it was lower in nasal swabs (44.7%) and saliva (23.1%). Test performance in NPS was largely dependent on the cycle threshold (Ct) in RT-PCR, with PPA>90% for Ct≤25 and ≥80% for Ct<30. In symptomatic patients, the PPA was 95% for Ct≤25; ≥85% for Ct<30, and 89% for the symptom triad of fever, cough and malaise. Performance was also dependent on age, with PPA of 100% in symptomatic patients >50 years with Ct<25. In asymptomatic patients, the PPA was 86% for Ct<25. In all cases, NPA was 100%. Conclusion: The nasopharyngeal Panbio COVID-19 antigen test performed at point-of-care is highly sensitive in symptomatic patients, particularly with Ct<30 and older age. The test was useful to identify asymptomatic patients with lower Ct values and therefore with contagious risk.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.16.20230003v1" target="_blank">Nasopharyngeal Panbio COVID-19 antigen performed at point-of-care has a high sensitivity in symptomatic and asymptomatic patients with higher risk for transmission and older age</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Deconditioning in people living with dementia during the COVID-19 pandemic: findings from the Promoting Activity, Independence and Stability in Early Dementia (PrAISED) process evaluation</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Background. Restrictions introduced in response to the COVID-19 pandemic led to increased risk of deconditioning in the general population. No empirical evidence of this effect however has been empirically gathered in people living with dementia. Objective. This study aims to identify the causes and effects of COVID-19-related deconditioning in people living with dementia. Design. Longitudinal phenomenological qualitative study. Subjects. Participants living with dementia, their carers and therapists involved in the Promoting Activity, Independence and Stability in Early Dementia (PrAISED) process evaluation during the COVID-19 pandemic. Methods. Qualitative interviews with participants were conducted remotely at two time points. The data were analysed through deductive thematic analysis. Results. Twenty-four participants living with dementia, 19 carers and 15 therapists took part in the study. A self-reinforcing pattern was common, whereby lockdown made the person apathetic, demotivated, socially-disengaged, and frailer. This reduced activity levels, which in turn reinforced the effects of deconditioning over time. Without external supporters, most participants lacked the motivation / cognitive abilities to keep active. Provided the proper infrastructure and support, some participants could use tele-rehabilitation to combat deconditioning. Conclusion. The added risks and effects of deconditioning on people with dementia require considerable efforts from policy makers and clinicians to ensure that they initiate and maintain physical activity in prolonged periods of social distancing. Delivering rehabilitation in the same way as before the pandemic might not be feasible or sustainable and innovative approaches must be found. Digital support for this population has shown promising results, but still remains a challenge.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.16.20231100v1" target="_blank">Deconditioning in people living with dementia during the COVID-19 pandemic: findings from the Promoting Activity, Independence and Stability in Early Dementia (PrAISED) process evaluation</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>The total number and mass of SARS-CoV-2 virions in an infected person</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Quantitatively describing the time course of the SARS-CoV-2 infection within an infected individual is important for understanding the current global pandemic and possible ways to combat it. Here we integrate the best current knowledge about the abundance of potential SARS-CoV-2 host cells and typical concentrations of virions in bodily fluids to estimate the total number and mass of SARS-CoV-2 virions in an infected person. We estimate that each infected person carries 10<sup>9</sup>-10<sup>11</sup> virions during peak infection, with a total mass of about 1 µg-0.1 mg, which curiously implies that all SARS-CoV-2 virions currently in the world have a mass of only 0.1-1 kg. Knowledge of the absolute number of virions in an infected individual can put into perspective parameters of the immune system response, minimal infectious doses and limits of detection in testing.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.16.20232009v1" target="_blank">The total number and mass of SARS-CoV-2 virions in an infected person</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Central and peripheral nervous system complications of COVID-19: A prospective tertiary center cohort with 3-month follow-up</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Objective: To systematically describe CNS and PNS complications in hospitalized COVID-19 patients. Methods: We conducted a prospective, consecutive, observational study of adult patients from a tertiary referral center with confirmed COVID-19. All patients were screened daily for neurological and neuropsychiatric symptoms during admission, at discharge and at 3-month follow-up. We classified complications as caused by SARS-CoV-2 neurotropism, immune-mediated or critical illness-related. Results: From April-September 2020, we enrolled 61 consecutively admitted COVID-19 patients, 35 (57%) of whom were referred to ICU for respiratory failure. Evaluation revealed a higher frequency of CNS/PNS symptoms in ICU patients compared to non-ICU patients. The most common CNS complication was encephalopathy (n=22, 36.1%), which was severe in 13 patients (GCS≤12), including 8 with akinetic mutism. Length of ICU admission was an independent predictor of encephalopathy (OR=1.23). Other CNS complications included ischemic stroke, a biopsy-proven acute necrotizing encephalitis, and transverse myelitis. The most common PNS complication was critical illness polyneuromyopathy (13.1%), with prolonged ICU stay as independent predictor (OR=1.14). Treatment-related PNS complications included meralgia paresthetica. Of 41 complications in total, 3 were classified as para/post-infectious. The remainder included cases secondary to critical illness or other causes (n=34) or without sufficient investigations (n=4). Cerebrospinal fluid was negative for SARS-CoV-2 RNA in all 5 patients investigated. Conclusions: CNS/PNS complications were common in hospitalized COVID-19 patients, particularly in ICU patients, and often attributable to critical illness. In cases with COVID-19 as the primary cause for neurological disease, there were no signs of viral neurotropism, but laboratory changes suggested autoimmune-mediated mechanisms.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.15.20231001v1" target="_blank">Central and peripheral nervous system complications of COVID-19: A prospective tertiary center cohort with 3-month follow-up</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>The autumn COVID-19 boost dates in Europe are linked to latitudes and not to temperatures pointing vitamin D as a contributing factor.</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Purpose: Determining the triggering factor of the sudden boost of the daily new COVID-19 cases arising in most European countries during 2020 Autumn. Methods: The dates of the boost were determined using a fitting of the two last months reported daily new cases in 18 European countries of latitude ranging from 39 to 62 degrees. Results: The study proves no correlation between the country boost date and its 2 weeks preceding temperature, but shows an impressive linear correlation with its latitude. The country boost date corresponds to the time when its sun UV daily dose drops below ≈30% of that of equator latitude. Conclusions: The previous studies, reporting a vitamin D blood level impact, compared COVID-19 severity between different patients populations and so can hardly discriminate whether the vitamin D blood level is a real factor of covid-19 severity or only a marker of another weakness being the primary severity factor. In contrary, the date of the boost is an intrapopulation observation and can thus only be triggered by a parameter globally affecting the population, i.e. the sun UV daily dose decreases. This result evidences that low vitamin blood D level is a contributing factor of COVID-19 severity.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.10.28.20221176v4" target="_blank">The autumn COVID-19 boost dates in Europe are linked to latitudes and not to temperatures pointing vitamin D as a contributing factor.</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Study of the Sudanese perceptions of COVID-19: Applying the Health Belief Model.</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Abstract Background COVID-19 a pandemic declared by WHO is the first in recent history pose challenges on public health. Health Belief Model is a psychosocial model explains and predicts health-related behaviours. This study aimed to explore the perceptions of the Sudanese on COVID-19-related preventive measures. Methods A Cross-sectional study using online-questionnaire was conducted between 1st-16th April 2020 among Sudanese adults. We used a snowball sampling technique starting from known professional and social media groups and individuals and then was distributed on various internet platforms. The survey instrument was based on HBM constructs. Results Some 877 individuals participated in the survey with a mean age of 37.8 more males mostly having a university education employed and residing in Khartoum. More than half of the participants scored high in almost all Health Belief Model constructs except for benefits of hand hygiene. The findings show that the HBM constructs are correlated to each other as well as to other socio-demographic factors. Self-efficacy correlated negatively with susceptibility while positively with severity benefits of and barriers to hand hygiene, benefits and barriers to social distancing respectively. Conclusion The findings show that the HBM constructs are correlated to each other as well as to other socio-demographic factors. Self-efficacy must be taken into account as a strong changing factor to susceptibility and severity perceptions. Correlations found in this study might help drive behaviour-changing efforts.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.05.28.20115477v2" target="_blank">Study of the Sudanese perceptions of COVID-19: Applying the Health Belief Model.</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Multiscale PHATE Exploration of SARS-CoV-2 Data Reveals Multimodal Signatures of Disease</strong> -
|
|||
|
|
<div>
|
|||
|
|
The biomedical community is producing increasingly high dimensional datasets, integrated from hundreds of patient samples, which current computational techniques struggle to explore. To uncover biological meaning from these complex datasets, we present an approach called Multiscale PHATE, which learns abstracted biological features from data that can be directly predictive of disease. Built on a continuous coarse graining process called diffusion condensation, Multiscale PHATE creates a tree of data granularities that can be cut at coarse levels for high level summarizations of data, as well as at fine levels for detailed representations on subsets. We apply Multiscale PHATE to study the immune response to COVID-19 in 54 million cells from 168 hospitalized patients. Through our analysis of patient samples, we identify CD16hiCD66lo neutrophil and IFN{gamma}+GranzymeB+ Th17 cell responses enriched in patients who die. Further, we show that population groupings Multiscale PHATE discovers can be directly fed into a classifier to predict disease outcome. We also use Multiscale PHATE-derived features to construct two different manifolds of patients, one from abstracted flow cytometry features and another directly on patient clinical features, both associating immune subsets and clinical markers with outcome.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2020.11.15.383661v1" target="_blank">Multiscale PHATE Exploration of SARS-CoV-2 Data Reveals Multimodal Signatures of Disease</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Deaths among COVID Cases in the United States: Racial and Ethnic Disparities Persist</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Using COVID-19 Case Surveillance Public Use Data by the Centers for Disease Control and Prevention, we estimate monthly age-adjusted case fatality rates (CFR) for four major groups: non-Hispanic (NH) whites, NH Blacks, NH Asians, and Hispanics. Available data show that CFRs across race/ethnic groups have become more equal over time. Nevertheless, racial and ethnic disparities persist. NH whites consistently experience lower CFRs; NH Blacks generally experience higher case fatality among younger patients; and NH Asians generally experience higher case fatality among older patients. Age-adjusted CFRs reveal dramatically different racial and ethnic disparities that are hidden by crude CFRs. Such adjustment is imperative for understanding COVID-199s toll.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.15.20232066v2" target="_blank">Deaths among COVID Cases in the United States: Racial and Ethnic Disparities Persist</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Background Although the COVID-19 pandemic peaked in March/April 2020 in France, the prevalence of infection is barely known. Herein, we assessed the serological response against the SARS-CoV-2 virus in a large population working in one institution of the Paris conurbation. We set up two high-throughput and sensitive methods to assess SARS CoV-2 Nucleoprotein and Spike protein-specific IgG response along with a pseudo-neutralization assay in sera. We studied 1847 participants who also answered a web-based survey on clinical symptoms. Methods and Results In May-July 2020, 11% (95% CI: 9.7-12.6) of serums were positive for IgG against the SARS-CoV-2 N and S protein and 9.5% (CI:8.2-11.0) were pseudo-neutralizer. The prevalence of immunization was 11.6% (CI:10.2-13.2) considering positivity in at least one assays. In 5% (CI:3.9-7.1) of RT-qPCR positive individuals, no systemic IgGs were detected. Among immune individuals, 21% had been asymptomatic. Anosmia and ageusia occurred in 52% of the IgG-positive individuals and in 3% of the negative ones. In contrast, 30% of the anosmia-ageusia cases were seronegative suggesting that the true prevalence of infection may reach 16.6%. In sera obtained 4-8 weeks after the first sampling anti-N and anti-S IgG titers and pseudo-neutralization activity declined by 31%, 17% and 53%, respectively with half-life of 35, 87 and 28 days, respectively. Conclusions The population studied being not particularly exposed to SARS-CoV-2 infection is representative of active workers in the Paris conurbation, suggesting that the current epidemiological models may underestimate the true prevalence of infection. The short lifespan of the serological systemic responses hinders retrospective assessment of the epidemic extent.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.10.25.20219030v2" target="_blank">High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Estimating individual risks of COVID-19-associated hospitalization and death using publicly available data</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
We describe a method to estimate individual risks of hospitalization and death attributable to non-household and household transmission of SARS-CoV-2 using available public data on confirmed-case incidence data along with estimates of the clinical fraction, timing of transmission, isolation adherence, secondary infection risks, contact rates, and case-hospitalization and case-fatality ratios. Using the method, we estimate that risks for a 90-day period at the median daily summertime U.S. county confirmed COVID-19 case incidence of 10.8 per 100,000 and pre-pandemic contact rates range from 0.4 to 8.9 per 100,000 for the four deciles of age between 20 and 60 years. The corresponding 90-day period risk of hospitalization ranges from 13.7 to 69.2 per 100,000. Assuming a non-household secondary infection risk of 4% and pre-pandemic contact rates, the share of transmissions attributable to household settings ranges from 73% to 78%. These estimates are sensitive to the parameter assumptions; nevertheless, they are reasonably comparable to the COVID-19 hospitalization and fatality rates observed over the time period. We conclude that individual risk of hospitalization and death from SARS-CoV-2 infection is calculable from publicly available data sources. Access to publicly reported infection incidence data by setting and other exposure characteristics along with setting specific estimates of secondary infection risk would allow for more precise individual risk estimation.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.06.06.20124446v3" target="_blank">Estimating individual risks of COVID-19-associated hospitalization and death using publicly available data</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Assessment of N95 respirator decontamination and re-use for SARS-CoV-2</strong> -
|
|||
|
|
<div>
|
|||
|
|
The unprecedented pandemic of SARS-CoV-2 has created worldwide shortages of personal protective equipment, in particular respiratory protection such as N95 respirators. SARS-CoV-2 transmission is frequently occurring in hospital settings, with numerous reported cases of nosocomial transmission highlighting the vulnerability of healthcare workers. In general, N95 respirators are designed for single use prior to disposal. Several groups have addressed the potential for re-use of N95 respirators from a mechanical or from a decontamination perspective. Here, we analyzed four different decontamination methods – UV radiation (260 – 285 nm), 70ºC heat, 70% ethanol and vaporized hydrogen peroxide (VHP) – for their ability to reduce contamination with infectious SARS-CoV-2 and their effect on N95 respirator function.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/phcsb/" target="_blank">Assessment of N95 respirator decontamination and re-use for SARS-CoV-2</a>
|
|||
|
|
</div></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Drug: Nafamostat Mesilate<br/><b>Sponsor</b>: Chong Kun Dang Pharmaceutical<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: AZD7442; Drug: Placebo<br/><b>Sponsors</b>: AstraZeneca; QuintilesIMS<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: AZD7442; Drug: Placebo<br/><b>Sponsors</b>: AstraZeneca; QuintilesIMS<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Effectiveness and Safety of Rhea Health Tone® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Dietary Supplement: Rhea Health Tone®<br/><b>Sponsors</b>: Universitas Padjadjaran; PT. Rhea Pharmaceutical Sciences Indonesia; Prodia Diacro Laboratories P.T.<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Hyperimmune Plasma for Patients With COVID-19</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Other: treated with hyperimmune plasma<br/><b>Sponsor</b>: ANNA FALANGA<br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: FSD201; Drug: Placebo<br/><b>Sponsor</b>: FSD Pharma, Inc.<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Intravenous Infusion of CAP-1002 in Patients With COVID-19</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Biological: CAP-1002; Biological: Placebo<br/><b>Sponsor</b>: Capricor Inc.<br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Drug: Clarithromycin 500mg; Drug: Azithromycin; Drug: Placebo<br/><b>Sponsor</b>: South Valley University<br/><b>Completed</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19 (PROVID-19)</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Dietary Supplement: Probiotics (2 strains 10x10^9 UFC); Dietary Supplement: Placebo (potato starch and magnesium stearate)<br/><b>Sponsors</b>: Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Lallemand Health Solutions<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: COVI-VAC; Other: Placebo<br/><b>Sponsor</b>: Codagenix, Inc<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID)</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Drug: Chloroquine<br/><b>Sponsor</b>: Fundacion Clinica Valle del Lili<br/><b>Active, not recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy and Safety of Acetyl L-Carnitine in COVID-19 Patients With Mild-to-Moderate Disease</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Dietary Supplement: Acetyl L-Carnitine<br/><b>Sponsor</b>: Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Early Versus Delayed Intubation of Patients With COVID-19</strong> - <b>Conditions</b>: COVID-19; Acute Hypoxemic Respiratory Failure<br/><b>Intervention</b>: Other: Endotracheal intubation<br/><b>Sponsor</b>: Evangelismos Hospital<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Randomised Study of Plasma Exchange in Severe COVID-19</strong> - <b>Condition</b>: COVID19<br/><b>Intervention</b>: Drug: OCTAPLAS<br/><b>Sponsor</b>: University College, London<br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Respiratory Distress</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Device: Hyperbaric Oxygen Therapy (HBOT)<br/><b>Sponsor</b>: NYU Langone Health<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Endothelial pulsatile shear stress is a backstop for COVID-19</strong> - There has not been any means to inhibit replication of the SARS-CoV-2 virus responsible for the rapid, deadly spread of the COVID-19 pandemic and an effective, safe, tested across diverse populations vaccine still requires extensive investigation. This review deals with the repurpose of a wellness technology initially fabricated for combating physical inactivity by increasing muscular activity. Its action increases pulsatile shear stress (PSS) to the endothelium such that the bioavailability of…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Pharmacological inhibition of MMP3 as a potential therapeutic option for COVID-19 associated acute respiratory distress syndrome</strong> - The high mortality of coronavirus disease 2019 (COVID-19) patients is due to their progression to cytokineassociated organ injuries, primarily the acute respiratory distress syndrome (ARDS). The uncertainties in the molecular mechanisms leading to the switch from the early virus infection to the advanced stage ARDS is a major gridlock in therapeutic development to reduce mortality. Previous studies in our laboratory have identified matrix metalloprotease-3 (MMP3) as an important mediator of…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19</strong> - The emergence and dissemination of SARS-CoV-2 has caused high mortality and enormous economic loss. Rapid development of new drug molecules is the need of hour to fight COVID-19. However, the conventional approaches of drug development are time consuming and expensive. Here, we have adopted a computational approach to identify lead molecules from nature. Ligands from natural compounds library available at Selleck Inc (L1400) have been screened for their ability to bind and inhibit the main…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Gain-of-function assay for SARS-CoV-2 M (pro) inhibition in living cells</strong> - The main protease, M ^(pro) , of SARS-CoV-2 is required to cleave the viral polyprotein into precise functional units for virus replication and pathogenesis. Here we demonstrate a quantitative reporter for M ^(pro) function in living cells, in which protease inhibition by genetic or chemical methods results in strong eGFP fluorescence. This robust gain-of-function system readily distinguishes between inhibitor potencies and can be scaled-up to high-throughput platforms for drug testing.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Copper(II) Inhibition of the SARS-CoV-2 Main Protease</strong> - In an analysis of the structural stability of the coronavirus main protease (Mpro), we identified regions of the protein that could be disabled by cobalt(III)-cation binding to histidines and cysteines [1]. Here we have extended our work to include copper(II) chelates, which we have docked to HIS 41 and CYS 145 in the Mpro active-site region. We have found stable docked structures where Cu(II) could readily bond to the CYS 145 thiolate, which would be lethal to the enzyme. We also started…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Synthesis of novel coumarin analogues: Investigation of molecular docking interaction of SARS-CoV-2 proteins with natural and synthetic coumarin analogues and their pharmacokinetics studies</strong> - The severe acute respiratory syndrome coronavirus, identified as SARS-CoV-2, initially established in Wuhan, China at the end of 2019, affects respiratory infections known as COVID-19. In an extraordinary manner, COVID-19 is affecting human life and has transformed a global public health issue into a crisis. Natural products are already recognized owing to the massive advantageous window and efficient antioxidant, antiviral immunomodulatory, and anti-inflammatory belongings. Additionally, the…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Role of angiotensin-converting enzyme 2 in neurodegenerative diseases during the COVID-19 pandemic</strong> - SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) uses the angiotensin-converting enzyme 2 (ACE2) receptor for infecting and spreading in humans. Studies have shown that the widespread expression of ACE2 in human tissues may be associated with organ function damage (e.g., lung, kidney, and stomach) in patients with coronavirus disease 2019 (COVID-19). However, in neurodegenerative diseases, whose pathogenesis is closely related to advanced age, ACE2 plays a neurotrophic and protective…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Covid-19, heat shock proteins, and autoimmune bullous diseases: a potential link deserving further attention</strong> - A link between Covid-19 and development of autoimmunity has been reported. A possible explanation could be molecular mimicry between SARS-CoV-2 and human proteins. Peptide sharing has been found between antigenic epitopes of this virus and heat shock proteins (Hsp) 60 and 90, both of which are associated with autoimmune diseases including those of the bullous type. In particular, there is evidence for the latter Hsp acting as a pathophysiological factor and treatment target in autoimmune…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Derangement of the coagulation process using subclinical markers and viscoelastic measurements in critically ill patients with coronavirus disease 2019 pneumonia and non-coronavirus disease 2019 pneumonia</strong> - : Systemic coagulation abnormalities including clotting activation and inhibition of anticoagulant factors have been observed in patients with pneumonia. In severe coronavirus disease 2019 (COVID-19) the alteration of coagulation parameters was associated with poor prognosis. We evaluated the difference in coagulopathy between critically ill patients with COVID-19 pneumonia (COVID group) and non-COVID-19 pneumonia (non-COVID group), using traditional coagulation markers and rotational…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phytogenic Products and Phytochemicals as a Candidate Strategy to Improve Tolerance to Coronavirus</strong> - Coronaviruses are the causative agents of many infectious diseases in human and animals. These included severe acute respiratory syndrome (SARS), avian infectious bronchitis (IBV) in poultry, Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19) in humans. These results had considerable death burdens and negative influences on social-economic life. Since the appearance of the outbreak of the COVID-19 pandemic, continuous investigations have been carried out by…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections</strong> - Background: Anti-inflammatory therapies such as IL-6 inhibition have been proposed for COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory response in infectious diseases may impair a desired host response and pre-dispose to secondary infections. Methods: We retrospectively reviewed the medical record of critically ill COVID-19 patients during an 8-week span and compared the prevalence of secondary infection and outcomes in patients who did and did not receive…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?</strong> - The COVID-19 disease is an unprecedented international public health emergency and considerably impacts the global economy and health service system. While awaiting the development of an effective vaccine, searching for the therapy for severe or critical COVID-19 patients is essential for reducing the mortality and alleviating the tension of the health service system. Cytokine release syndrome (CRS) induced by elevated interleukin-6 was recognized to underscore the pathology of severe COVID-19…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Identification of a New Potential SARS-COV-2 RNA-Dependent RNA Polymerase Inhibitor via Combining Fragment-Based Drug Design, Docking, Molecular Dynamics, and MM-PBSA Calculations</strong> - The world has recently been struck by the SARS-Cov-2 pandemic, a situation that people have never before experienced. Infections are increasing without reaching a peak. The WHO has reported more than 25 million infections and nearly 857,766 confirmed deaths. Safety measures are insufficient and there are still no approved drugs for the COVID-19 disease. Thus, it is an urgent necessity to develop a specific inhibitor for COVID-19. One of the most attractive targets in the virus life cycle is the…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain</strong> - The coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by the severe acute respiratory syndrome coronavirus (SARS)-CoV-2. In light of the urgent need to identify novel approaches to be used in the emergency phase, we have embarked on an exploratory campaign aimed at repurposing natural substances and clinically available drugs as potential anti-SARS-CoV2-2 agents by targeting viral proteins. Here we report on a strategy based on the virtual screening of druggable pockets…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Innate Immunity and Influenza A Virus Pathogenesis: Lessons for COVID-19</strong> - There is abundant evidence that the innate immune response to influenza A virus (IAV) is highly complex and plays a key role in protection against IAV induced infection and illness. Unfortunately it also clear that aspects of innate immunity can lead to severe morbidity or mortality from IAV, including inflammatory lung injury, bacterial superinfection, and exacerbation of reactive airways disease. We review broadly the virus and host factors that result in adverse outcomes from IAV and show…</p></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>AN EFFICIENT METHODOLOGY TO MANAGE THE ADMISSIONS IN HOSPITALS DURING THE PANDEMICS SUCH AS COVID 19</strong> -</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>SARS-CoV-2 예방을 위한 mRNA기반 항원보강제 혼합물 합성 방법</strong> - 본 발명은 SARS-CoV-2(코로나 바이러스) 예방을 위한 mRNA 항원보강제에 관한 것으로 코로나 바이러스에 대한 백신으로서 상기의 항원에 대한 예방을 목적으로 하고 있다. 아이디어에는 보강제에 해당하는 완전프로인트항원보강제(CFA)와 불완전프로인트항원보강제(IFA), 번역과 안정성의 최적화가 된 mRNA, mRNA 운반체, 양이온성 지질 나노입자(lipid nanoparticles)로 구성되며 기존의 백신에 비해 효율성과 안정성의 측면에서 더 향상된 효과를 가지고 있다.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vorrichtung zum Reinigen und/oder Desinfizieren von Objekten</strong> -</p>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Vorrichtung (1) zum Desinfizieren von Objekten mit einer Basiseinheit (2), mit einem Aufnahmebehälter (4) für Wasser, welcher an der Basiseinheit (2) montierbar und von der Basiseinheit demontierbar ist, mit einer Objekthalterung (6) zum Halten und/oder Stützen der Objekte (10), wobei diese Objekthalterung (6) in dem Aufnahmebehälter montierbar ist und mit einer elektrisch betriebenen Reinigungseinrichtung (8), welche in dem Wasser befindliche Objekte zumindest mittelbar reinigt oder desinfiziert, wobei diese Reinigungseinrichtung in der Basiseinheit befindliche Erzeugungsmittel zum Erzeugen einer elektrischen Spannung aufweist sowie einen Plasmagenerator und/oder eine Ultraschallerzeugungseinheit.</p></li>
|
|||
|
|
</ul>
|
|||
|
|
<img alt="embedded image" id="EMI-D00000"/>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Methods for treating Arenaviridae and Coronaviridae virus infections</strong> - Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I:</li>
|
|||
|
|
</ul>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">wherein the ’ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.</p>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Atemschutz-Baukastensystem</strong> -
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Atemschutz-Baukastensystem, das aufweist:</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">eine auf zumindest Mund und Nase einer Person aufsetzbare Maske (1), die einen Eingang (11) und einen Ausgang (12) aufweist, und</li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">mindestens einen Schlauch (3, 31, 32),</li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">wobei sämtliche Komponenten des Atemschutz-Baukastensystems modular ausgebildet und über Steckverbindungen oder Schraubverbindungen (115, 125, 155, 165, 175, 215, 315, 75, 915) miteinander verbindbar sind, um der Maske (1) Luft über deren Eingang (11) zuzuführen und/oder ausgeatmete Luft vom Ausgang (12) der Maske (1) wegzuführen.</li>
|
|||
|
|
</ul>
|
|||
|
|
<img alt="embedded image" id="EMI-D00000"/>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vorrichtung zur Übergabe und Dekontamination von mit Krankheitserregern kontaminierten Gegenständen oder Erzeugnissen</strong> -
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Vorrichtung zur Übergabe von mit Krankheitserregern kontaminierten Gegenständen oder Erzeugnissen nach einer Dekontamination, umfassend eine Einrichtung zur Dekontamination der mit Krankheitserregern kontaminierten Gegenstände oder Erzeugnisse mit mindestens einer UV-Strahlungsquelle (24), eine Durchzugseinrichtung mit Ein- und/oder Ausgabebereichen für die kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse, dadurch gekennzeichnet, dass die Durchzugseinrichtung im Eingang bzw. im Ausgang zum Ein- und/oder Ausgabebereich angeordnete sich paarweise gegenüberliegende Walzen (17) und Räder (4) umfasst, die zum Einzug bzw. zur Ausgabe der kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse vorgesehen sind, wobei die Walzen (17) und die Räder (4) durch im Ein- und/oder Ausgabebereich angeordnete Sensoren (23) und einer elektronische Kontrolleinheit (27) in Bewegung bringbar sind, wobei die Gegenstände oder Erzeugnisse in den Bereich der Einrichtung zur Dekontamination förderbar sind, der zwischen den paarweise angeordneten Walzen (17) und Rädern (4) vorgesehen ist, welcher sich gegenüberliegende Platten (25) aus Quarzglas oder einem UV-transparenten Polymermaterial, wie Graphen oder Kunstglas umfasst, über bzw. unter welchen die UV-Strahlungsquelle (24) angeordnet ist, welche als UVC-LED-Leiste und/oder Modul mit mindestens einer LED-Lampe ausgebildet ist.</p></li>
|
|||
|
|
</ul>
|
|||
|
|
<img alt="embedded image" id="EMI-D00000"/>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물</strong> - 본 발명은 화학식 1로 표시되는 화합물, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환 예방 또는 치료용 약학적 조성물을 제공한다. [화학식 1] .</p>
|
|||
|
|
<pre><code> JPEG
|
|||
|
|
112020094463686-pat00017.jpg
|
|||
|
|
48
|
|||
|
|
135</code></pre></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>新型冠状病毒中和性抗体滴度检测ELISA试剂盒</strong> - 本发明提供一种新型冠状病毒中和性抗体滴度检测ELISA试剂盒，其中包括：包被有生物素‑链霉亲和素标记的人ACE2蛋白的酶标板、辣根过氧化酶标记的新型冠状病毒RBD蛋白、新型冠状病毒中和性抗体阳性对照、包被液、洗涤液、稀释液、封闭液、显色液和终止液等。该试剂盒具有成本低，操作简单，高灵敏度、高特异性、高准确度的特点，可用于新型冠状病毒中和抗体的批量、快速检测。</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Reagenzien und Verwendungen zur Diagnose einer SARS-CoV-2-Infektion</strong> -</p>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Diagnostisch nützlicher Träger umfassend ein Polypeptid umfassend SEQ ID NO1 oder eine Variante davon, die an einen Antikörper gegen SEQ ID NO1 aus einer Probe von einem Patienten binden kann, der an einer SARS-CoV-2-Infektion leidet, wobei das Polypeptid bevorzugt auf der Festphase des Trägers immobilisiert ist.</p></li>
|
|||
|
|
</ul>
|
|||
|
|
<img alt="embedded image" id="EMI-D00000"/>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Reagenzien und Verwendungen zur Diagnose einer SARS-CoV-2-Infektion</strong> -
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Verwendung eines Polypeptides umfassend SEQ ID NO1 oder eine Variante davon, die an einen Antikörper gegen SED ID NO1 aus einer Probe von einem Patienten binden kann, zur Herstellung eines diagnostischen Kits.</p></li>
|
|||
|
|
</ul>
|
|||
|
|
<img alt="embedded image" id="EMI-D00000"/>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
|||
|
|
|
|||
|
|
|
|||
|
|
<script>AOS.init();</script></body></html>
|